Herbst RS - Search Results

1

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Grant MJ, Herbst RS, Goldberg SB. Grant MJ, et al. Among authors: herbst rs. Nat Rev Clin Oncol. 2021 Oct;18(10):625-644. doi: 10.1038/s41571-021-00520-1. Epub 2021 Jun 24. Nat Rev Clin Oncol. 2021. PMID: 34168333 Review.

2

Gefitinib--a novel targeted approach to treating cancer.

Herbst RS, Fukuoka M, Baselga J. Herbst RS, et al. Nat Rev Cancer. 2004 Dec;4(12):956-65. doi: 10.1038/nrc1506. Nat Rev Cancer. 2004. PMID: 15573117 Review.

3

Surgery: Future directions in multimodality therapy for NSCLC.

Tsao AS, Roth JA, Herbst RS. Tsao AS, et al. Among authors: herbst rs. Nat Rev Clin Oncol. 2010 Jan;7(1):10-2. doi: 10.1038/nrclinonc.2009.174. Nat Rev Clin Oncol. 2010. PMID: 20029443

4

Highlights in NSCLC From the IASLC (International Association for the Study of Lung Cancer) 14th World Conference on Lung Cancer.

Herbst RS. Herbst RS. Clin Adv Hematol Oncol. 2011 Sep;9(9 Suppl 23):1-24. Clin Adv Hematol Oncol. 2011. PMID: 22362179 No abstract available.

5

A step towards treating KRAS-mutant NSCLC.

Goldberg SB, Schlessinger J, Boyer JL, Herbst RS. Goldberg SB, et al. Among authors: herbst rs. Lancet Oncol. 2013 Jan;14(1):3-5. doi: 10.1016/S1470-2045(12)70528-4. Epub 2012 Nov 28. Lancet Oncol. 2013. PMID: 23200176 No abstract available.

6

Angiogenesis inhibition and lung-cancer therapy.

Onn A, Bar J, Herbst RS. Onn A, et al. Among authors: herbst rs. Lancet Oncol. 2014 Feb;15(2):124-5. doi: 10.1016/S1470-2045(14)70010-5. Lancet Oncol. 2014. PMID: 24480554 No abstract available.

7

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.

Gettinger S, Herbst RS. Gettinger S, et al. Among authors: herbst rs. Cancer J. 2014 Jul-Aug;20(4):281-9. doi: 10.1097/PPO.0000000000000063. Cancer J. 2014. PMID: 25098289 Review.

8

Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway.

Kris MG, Arenberg DA, Herbst RS, Riely GJ. Kris MG, et al. Among authors: herbst rs. Clin Lung Cancer. 2014 Nov;15(6):475. doi: 10.1016/j.cllc.2014.08.001. Clin Lung Cancer. 2014. PMID: 25306384

9

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.

Henick BS, Herbst RS, Goldberg SB. Henick BS, et al. Among authors: herbst rs. Expert Opin Ther Targets. 2014 Dec;18(12):1407-20. doi: 10.1517/14728222.2014.955794. Epub 2014 Oct 21. Expert Opin Ther Targets. 2014. PMID: 25331677 Review.

10

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Herbst RS, et al. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. Nature. 2014. PMID: 25428504 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

428 results

Search Page